A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- Sponsors AEON Biopharma
- 29 May 2024 Status changed from active, no longer recruiting to discontinued as per AEON Biopharma media release
- 29 May 2024 According to AEON Biopharma media release, patients will be monitored for safety purposes through the 12-week period following their last treatment.
- 14 May 2024 According to an AEON Biopharma media release, study has enrolled a total of 492 patients across approximately 50 sites in the United States, Canada and Australia.